EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $25.71 Average Price Target from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has received an average rating of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $25.71.

A number of equities analysts have weighed in on the company. Chardan Capital upped their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price on the stock. Jefferies Financial Group started coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price for the company. Robert W. Baird decreased their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its position in EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after purchasing an additional 4,172 shares during the period. Greenwich Wealth Management LLC purchased a new stake in EyePoint Pharmaceuticals during the second quarter valued at about $94,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after buying an additional 7,953 shares during the last quarter. Cyndeo Wealth Partners LLC purchased a new position in shares of EyePoint Pharmaceuticals in the third quarter worth about $100,000. Finally, Arizona State Retirement System increased its holdings in shares of EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $115,000 after buying an additional 1,171 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $7.33 on Wednesday. The company has a market capitalization of $500.28 million, a PE ratio of -3.67 and a beta of 1.46. EyePoint Pharmaceuticals has a 52-week low of $6.90 and a 52-week high of $30.99. The business’s fifty day moving average is $9.59 and its 200 day moving average is $9.06.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.